Litigation Details for BAUSCH HEALTH IRELAND LIMITED v. MSN LABORATORIES PRIVATE LTD. (D.N.J. 2024)

BAUSCH HEALTH IRELAND LIMITED v. MSN LABORATORIES PRIVATE LTD. (D.N.J. 2024)

Docket		Date Filed	2024-12-16
Court	District Court, D. New Jersey	Date Terminated	2025-01-06
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Jessica S. Allen
Patents	12,146,003
Link to Docket	External link to docket

Details for BAUSCH HEALTH IRELAND LIMITED v. MSN LABORATORIES PRIVATE LTD. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-12-16				External link to document

BAUSCH HEALTH IRELAND LIMITED v. MSN LABORATORIES PRIVATE LTD. (2:24-cv-11179): Litigation Summary, Filing Posture, and IP/Regulatory Exposure

Last updated: June 20, 2026

Bausch Health Ireland Limited (BHIL) sued MSN Laboratories Private Ltd. under case number 2:24-cv-11179. The matter is pending in federal court and is characterized procedurally as patent/IP litigation tied to generic or biosimilar market entry risk. No final merits rulings are reflected in the docket state provided here.

What is the lawsuit BAUSCH HEALTH IRELAND LIMITED v. MSN LABORATORIES PRIVATE LTD. (2:24-cv-11179) about?

Answer: The case is a federal patent infringement action brought by BHIL against MSN Laboratories Private Ltd. No final claim construction, infringement finding, or injunction status is available from the information provided in the request.

Parties and roles

• Plaintiff: Bausch Health Ireland Limited (BHIL)
• Defendant: MSN Laboratories Private Ltd.
• Court / case number: 2:24-cv-11179
• Stage: Pending (no dispositive outcome provided)

Core allegations to expect in this docket type

For actions carrying this docket structure, the complaint typically asserts that the defendant’s proposed or marketed product infringes one or more patents listed for the reference product, often with a Paragraph IV-style premise when FDA approvals are involved. The specific asserted patents, claims, and product linkage are not stated in the prompt.

What patents are asserted in 2:24-cv-11179?

Answer: The prompt does not include the asserted patent numbers, listed Orange Book patents, or infringement bases. Without those identifiers, a complete and accurate claim chart level summary cannot be produced.

What a complete infringement snapshot would normally include

• Asserted patent numbers
• Patent assignee(s)
• Asserted claims
• Infringed product features (dosage form, strength, delivery system, formulation parameters)
• Inducement/contributory theories (if pleaded)

No such details are provided here.

What is the procedural posture of 2:24-cv-11179 (motions, hearings, and deadlines)?

Answer: The prompt provides only the case caption and docket number. It does not include docket entries, schedules, or motion results, so an accurate procedural timeline cannot be generated.

What to pull from the docket (not provided here)

• Complaint filing date
• Service and answer deadlines
• Rule 12 motions (dismissal, venue, jurisdiction)
• Markman schedule (if claim construction is set)
• Preliminary injunction requests
• Case management order
• Discovery deadlines
• Summary judgment motions

Those items are not present in the supplied information.

Did BHIL seek a preliminary injunction in 2:24-cv-11179?

Answer: The supplied information does not indicate whether BHIL moved for or obtained any preliminary injunctive relief.

Typical injunction triggers (not confirmed here)

• FDA approval or launch timing allegations
• Likelihood of success on the merits
• Irreparable harm findings
• Bond and scope of proposed injunction

How does this case affect generic entry risk for MSN Laboratories Private Ltd.?

Answer: The existence of the infringement suit creates ongoing market-entry and launch-timing risk for MSN, but the specific entry scenario (ANDA filing linkage, FDA approval status, or whether the action is tied to a Paragraph IV notice) is not contained in the prompt.

Launch-risk channels usually impacted

• Design-around pressure if formulation or method-of-use claims are asserted
• Bottlenecks from injunction or settlement constraints
• Regulatory timing tied to FDA approval dates and patent litigation outcomes

No FDA linkage details are provided here.

What is the Orange Book status of the relevant BHIL product(s) in 2:24-cv-11179?

Answer: Orange Book listing status is not included in the prompt, so a verified listing-by-listing summary cannot be produced.

What would be required for an Orange Book-backed analysis

• Reference listed drug (RLD) name
• Orange Book patent numbers for composition, formulation, and method-of-use
• Expiration dates
• Regulatory exclusivity (NCE/NP exclusivity, pediatric exclusivity)
• Which patents are asserted in the complaint
• Any co-pending FDA litigation or stays

None of this information is provided here.

What is the likely patent estate strength behind BHIL’s claims?

Answer: Patent estate strength cannot be assessed without the asserted patents and their jurisdictions, remaining term, claim breadth, and prosecution history indicators.

What strength metrics require (not provided)

• Patent expiration dates and remaining term
• Whether patents are composition-of-matter vs. formulation vs. method-of-use
• Claim count and breadth
• Prior art references and prosecution amendments
• Litigation history of the patents (validity/infringement outcomes)
• Claim construction tendencies in related cases

What generic entry risks exist for this drug if patents expire or claims are narrowed?

Answer: Entry risks depend on the asserted patent set, their expiration, and the possibility of design-around. Those inputs are not in the prompt, so only a qualitative statement is possible, which is not sufficient for a litigation-grade analysis.

How do settlement agreements usually play out in this type of BHIL v. generic defendant litigation?

Answer: Settlement outcomes are not described in the prompt, so no specific agreement terms, covenants not to sue, or no-At-Risk launch provisions can be stated.

Typical terms (not confirmed for this case)

• Licensed entry dates
• Agreed design-around scopes
• Compensation and reverse-payment structures
• Dismissal and stipulation of non-infringement after launch permissions

What patent litigation affects other Bausch Health products similarly to this case?

Answer: The prompt does not list related cases or shared patent families, so cross-litigation mapping cannot be completed.

What would be required

• Shared assignee and patent families
• Related dockets in the same district
• Consolidated claim construction or similar scheduling

None of that is provided here.

Key facts table (from the provided prompt)

Item	Value
Plaintiff	Bausch Health Ireland Limited
Defendant	MSN Laboratories Private Ltd.
Case number	2:24-cv-11179
Jurisdiction	Federal district court (district not specified in prompt)
Status	Pending (no disposition provided)
Asserted patents	Not provided
FDA/Orange Book linkage	Not provided
Claims/infringement theory	Not provided

Key Takeaways

• BHIL is the plaintiff and MSN Laboratories Private Ltd. is the defendant in 2:24-cv-11179.
• The matter is pending based on the prompt, with no outcomes, injunctions, or claim rulings included.
• A litigation-grade analysis of asserted patents, remaining term, Paragraph IV posture, and generic entry impact cannot be produced from the information provided.

FAQs

1. What is the fastest way to identify the asserted patents in 2:24-cv-11179?
   Review the complaint’s “Patents-in-Suit” section and the Exhibit listing asserted claims (not provided in the prompt).

2. Do cases like this usually include Paragraph IV-style allegations?
   Many generic entry patent suits do, but the prompt does not confirm Paragraph IV notices for this docket.

3. Can a launch be blocked without an injunction?
   Yes, litigation can deter “at-risk” launch depending on FDA status and court orders; the prompt does not include orders.

4. How are method-of-use patents treated versus composition or formulation patents in infringement litigation?
   Treatment depends on claim construction; the asserted patent types are not provided here.

5. What schedule milestones typically drive settlement leverage in generic patent suits?
   Markman, preliminary injunction hearings, and summary judgment timelines; no scheduling details are included in the prompt.

---

References

1. Case caption and docket identifier provided in prompt: BAUSCH HEALTH IRELAND LIMITED v. MSN LABORATORIES PRIVATE LTD., 2:24-cv-11179.